Radioimmunotherapy

Radioimmunotherapy
Schematic of radioimmunotherapy (RIT)
Other namesRIT
ICD-9-CM92.28
MeSHD016499

Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell.[1] It is a form of unsealed source radiotherapy. In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to the tumor cells. The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells while decreasing the dose to normal tissues. By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal cells.

History of available agents

NameDescriptionFDA statusEMA status
Ibritumomab tiuxetan (Zevalin)monoclonal antibody anti-CD20 conjugated to a molecule that chelates Yttrium-90.Approved (2002)[2][3]Authorised (2004)[4]
Iodine (131I) tositumomab (Bexxar)links a molecule containing Iodine-131 to an anti-CD20 monoclonal antibodyApproved (2003)[5]
Withdrawn (2014)[6]		Orphan drug (2003)
Withdrawn (2015)[7]
Lutetium (177Lu) lilotomab satetraxetan (Betalutin)combination of lutetium-177 and an anti-CD37 monoclonal antibodyFast track (2020)[8]Orphan drug (2020)[9]

131I tositumomab and 90Y ibritumomab tiuxetan were the first agents of radioimmunotherapy, and they were approved for the treatment of refractory non-Hodgkin's lymphoma. This means they are used in patients whose lymphoma is refractory to conventional chemotherapy and the monoclonal antibody rituximab.

Agents in clinical development

A set of radioimmunotherapy drugs that rely upon an alpha-emitting isotope (e.g., bismuth-213 or, preferably, actinium-225), rather than a beta emitter, as the killing source of radiation is being developed. Several phase II clinical trials for the treatment of acute myeloid leukemia have been carried out using alpha-emitting RITs.[10][11]

90Y-FF-21101 is a monoclonal antibody against P-cadherin radiolabeled with yttrium-90.[12] It is one of several RIT treatments under investigation intending to treat solid tumors.[13] A phase I clinical trial began in 2015.[14]

Other applications (non-approved indications)

Other types of cancer for which RIT has therapeutic potential include prostate cancer,[15] metastatic melanoma,[16] ovarian cancer,[17] neoplastic meningitis,[17] leukemia,[18] high-grade brain glioma,[19] and metastatic colorectal cancer.[20]

References

  1. ↑ Milenic, Diane E.; Brady, Erik D.; Brechbiel, Martin W. (June 2004). "Antibody-targeted radiation cancer therapy". Nature Reviews Drug Discovery. 3 (6): 488–499. doi:10.1038/nrd1413. PMID 15173838. S2CID 22166498.
  2. ↑ FIbritumomab Tiuxetan (Zevalin™) Radioimmunotherapy of Non-Hodgkin’s Lymphoma
  3. ↑ Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for Non-Hodgkin's Lymphoma. Clin Med Res. 2005 Aug;3(3):157-65.
  4. ↑ "Zevalin". European Medicines Agency. Retrieved 8 November 2020.
  5. ↑ Tositumomab and Iodine I 131 Tositumomab - Product Approval Information - Licensing Action
  6. ↑ "Why Good Drugs Sometimes Fail: The Bexxar Story". 2013-08-26.
  7. ↑ "EU/3/03/136". European Medicines Agency. Retrieved 8 November 2020.
  8. ↑ "FDA grants fast track status to Betalutin for marginal zone lymphoma". Healio. 29 June 2020.
  9. ↑ "EU/3/20/2280". European Medicines Agency. Retrieved 8 November 2020.
  10. ↑ Bodet-Milin, Caroline; Kraeber-Bodéré, Françoise; Eugène, Thomas; Guérard, François; Gaschet, Joëlle; Bailly, Clément; Mougin, Marie; Bourgeois, Mickaël; Faivre-Chauvet, Alain; Chérel, Michel; Chevallier, Patrice (March 2016). "Radioimmunotherapy for Treatment of Acute Leukemia". Seminars in Nuclear Medicine. 46 (2): 135–146. doi:10.1053/j.semnuclmed.2015.10.007. PMID 26897718.
  11. ↑ Pandit-Taskar, Neeta (December 2019). "Targeted Radioimmunotherapy and Theranostics with Alpha Emitters". Journal of Medical Imaging and Radiation Sciences. 50 (4): S41–S44. doi:10.1016/j.jmir.2019.07.006. PMID 31451417.
  12. ↑ Subbiah, Vivek; Erwin, William; Mawlawi, Osama; McCoy, Asa; Wages, David; Wheeler, Catherine; Gonzalez-Lepera, Carlos; Liu, Holly; Macapinlac, Homer; Meric-Bernstam, Funda; Hong, David S.; Pant, Shubham; Le, Dao; Santos, Elmer; Gonzalez, Jose; Roszik, Jason; Suzuki, Takeaki; Subach, Ruth Ann; Madden, Timothy; Johansen, Mary; Nomura, Fumiko; Satoh, Hirokazu; Matsuura, Tadashi; Kajita, Masamichi; Nakamura, Eri; Funase, Yuichi; Matsushima, Satoshi; Ravizzini, Gregory (18 August 2020). "Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90 Y-FF-21101 Monoclonal Antibody in Solid Tumors". Clinical Cancer Research. 26 (22): 1078–0432.CCR–20-0037. doi:10.1158/1078-0432.CCR-20-0037. PMID 32816889.
  13. ↑ Zaheer, Javeria; Kim, Hyeongi; Lee, Yong-Jin; Kim, Jin Su; Lim, Sang Moo (8 November 2019). "Combination Radioimmunotherapy Strategies for Solid Tumors". International Journal of Molecular Sciences. 20 (22): 5579. doi:10.3390/ijms20225579. PMC 6888084. PMID 31717302.
  14. ↑ A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer
  15. ↑ Smith-Jones PM. Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol Imaging. 2004 Dec;48(4):297-304.
  16. ↑ Dadachova E, Nosanchuk JD, Shi L, Schweitzer AD, Frenkel A, Nosanchuk JS, and Casadevall A. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a monoclonal antibody to melanin. Proc Natl Acad Sci USA 2004;101: 14865-70.
  17. 1 2 Zalutsky MR, Pozzi OR. Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging. 2004 Dec;48(4):289-96.
  18. ↑ Burke JM, Jurcic JG. Radioimmunotherapy of leukemia. Adv Pharmacol. 2004;51:185-208.
  19. ↑ Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):972-5.
  20. ↑ Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5842-52.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.